16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
07:00 , Jun 13, 2016 |  BioCentury  |  Product Development

Basket cases

Both the Genentech Inc. unit of Roche and Novartis AG are using basket trials to study targeted cancer agents more efficiently. Genentech's initial forays could yield rare subpopulation data to bring its marketed therapies into...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Defactinib: Phase II suspended enrollment

Verastem stopped enrollment in the double-blind, international, pivotal Phase II COMMAND trial in patients with MPM after a pre-planned interim analysis showed that twice-daily 400 mg oral defactinib led to no difference in PFS, the...
00:52 , Sep 29, 2015 |  BC Extra  |  Clinical News

Verastem halts mesothelioma trial

Verastem Inc. (NASDAQ:VSTM) fell $3.82 (67%) to $1.85 on Monday after it halted enrollment of the Phase II COMMAND study of defactinib ( VS-6063) to treat mesothelioma due to futility. A DSMB found no difference...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Overcoming origins

The start of two large-scale trials enrolling patients whose tumors share a common molecular signature regardless of the tissue of origin reflects tremendous progress in both the understanding of cancer biology and the availability of...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Neurofibromin 1 (NF1)

Cancer INDICATION: Neurofibromatosis Mouse studies suggest MEK inhibitors could help treat neurofibromatosis type 1, which is caused by loss-of-function mutations in the tumor suppressor gene NF1. In neonatal mice with neuronal precursor-specific knockout of NF1, treatment...